TerminatedPhase 2

Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

Stopped: slow enrollment and inability to reach the planned sample size within the expected timeframe

China98 participantsStarted 2021-09-30

Plain-language summary

Acute kidney injury is a frequent complication after coronary artery bypass grafting (CABG). Roxadustat is a prolyl hydroxylase inhibitor (PHI) which can stabilize hypoxia-inducible factor (HIF) and improve the hypoxic tolerance of tissues. Roxadustat has shown effect in reducing acute kidney injury in animal studies. This study aims to evaluate the efficacy of administration of Roxadustat before surgery in the prevention of acute kidney injury after CABG.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-80 years old * non-emergent CABG and planned cardiopulmonary bypass (CPB) * eGFR\>15ml/min/1.73m2 Exclusion Criteria: * pregnancy or breast feeding * malignancy * severe liver dysfunction * acute kidney injury before randomization * uncontrolled hypertension

What they're measuring

acute kidney injury

Timeframe: 0-48 hours after surgery

Trial details

NCT IDNCT05010460

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-20

View on ClinicalTrials.gov More Coronary Artery Bypass trials